ComplianceOnline

483 sent to Jilin Shulan Synthetic Pharmaceutical Co.

  • By: Staff Editor
  • Source: www.fda.gov
Webinar All Access Pass Subscription Abstract:

Warning letter sent to Jilin Shulan Synthetic Pharmaceutical Co. regarding significant deviations from Current Good Manufacturing Practice (CGMP) for the manufacture of APIs.

Bookmark and Share
Best Sellers
You Recently Viewed
    Loading